Eli Lilly has unveiled plans to invest more than $1 billion over the coming years to new contract manufacturing in India, expanding patients’ access to innovative medicines worldwide. This strategic investment will further strengthen the manufacturing and supply capabilities to support their evolving portfolio.
As part of this expansion, Lilly will establish a new Manufacturing and Quality hub in Hyderabad, designed to provide advanced technical oversight for its contract manufacturing network across the country. Recruitment for this new facility will commence immediately, with openings for a diverse range of roles including engineers, chemists, analytical scientists, quality control and assurance professionals, and management.
Patrik Jonsson, Executive Vice President and President of Lilly International added, “We are making significant investments worldwide to increase manufacturing and medicine supply capacity, ensuring patients have access to the medicines they need.”
This $1 billion investment marks a significant milestone for Lilly’s growth strategy, empowering India’s pharmaceutical ecosystem while enhancing global availability of life-changing therapies.
